GSA Capital Partners LLP bought a new position in shares of Insmed Incorporated (NASDAQ:INSM – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,152 shares of the biopharmaceutical company's stock, valued at approximately $286,000.
Several other institutional investors and hedge funds have also made changes to their positions in INSM. Point72 Hong Kong Ltd acquired a new position in shares of Insmed during the 4th quarter worth approximately $45,000. Advisor Group Holdings Inc. boosted its holdings in shares of Insmed by 56.4% during the 4th quarter. Advisor Group Holdings Inc. now owns 2,140 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 772 shares during the last quarter. Duality Advisers LP acquired a new position in shares of Insmed during the 1st quarter worth approximately $209,000. Calton & Associates Inc. boosted its holdings in shares of Insmed by 15.7% during the 1st quarter. Calton & Associates Inc. now owns 9,801 shares of the biopharmaceutical company's stock worth $230,000 after purchasing an additional 1,331 shares during the last quarter. Finally, First Republic Investment Management Inc. boosted its holdings in shares of Insmed by 10.7% during the 4th quarter. First Republic Investment Management Inc. now owns 8,583 shares of the biopharmaceutical company's stock worth $234,000 after purchasing an additional 832 shares during the last quarter.
Get
Insmed alerts:
Insider Transactions at Insmed
In other news, CEO William Lewis sold 216,800 shares of the company's stock in a transaction on Monday, August 8th. The stock was sold at an average price of $27.84, for a total transaction of $6,035,712.00. Following the sale, the chief executive officer now owns 256,716 shares of the company's stock, valued at $7,146,973.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 314,355 shares of company stock valued at $8,279,853. 4.40% of the stock is currently owned by company insiders.
Insmed Stock Down 1.2 %
NASDAQ:INSM opened at $23.89 on Wednesday. The company has a quick ratio of 5.34, a current ratio of 5.93 and a debt-to-equity ratio of 18.24. The stock's fifty day moving average is $23.61 and its two-hundred day moving average is $22.45. Insmed Incorporated has a 52 week low of $16.41 and a 52 week high of $34.44. The stock has a market capitalization of $2.87 billion, a price-to-earnings ratio of -6.81 and a beta of 1.91.
Insmed (NASDAQ:INSM – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.09. Insmed had a negative return on equity of 154.14% and a negative net margin of 188.04%. The company had revenue of $65.20 million for the quarter, compared to analysts' expectations of $58.92 million. During the same period in the prior year, the firm earned ($0.94) earnings per share. The firm's revenue was up 43.6% compared to the same quarter last year. Research analysts anticipate that Insmed Incorporated will post -3.4 EPS for the current year.
Analyst Ratings Changes
INSM has been the topic of a number of recent analyst reports. Credit Suisse Group upped their price objective on Insmed to $58.00 in a report on Tuesday, August 9th. The Goldman Sachs Group decreased their price objective on Insmed from $56.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 24th. Finally, Morgan Stanley decreased their price objective on Insmed from $46.00 to $41.00 and set an "overweight" rating on the stock in a report on Friday, July 15th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $50.86.
Insmed Company Profile
(Get Rating)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Articles
- Get a free copy of the StockNews.com research report on Insmed (INSM)
- How the Pandemic Forced F5 to Flex its Software Side
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM – Get Rating).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
